Loading
Colorectal Cancer Surgical Treatments / Gastric Cancer Management and Outcomes · Journal article
Updates in Surgery · August 11, 2026
A consensus or society position rather than new primary data.
This narrative review identifies lymphovascular invasion and high-grade tumour budding as the most consistent independent predictors of lymph node metastasis in T1 colorectal cancer, with poor differentiation and submucosal invasion depth as additional risk factors. The authors propose a structured pathology report incorporating these features and morphology to guide risk-adapted decisions on completion surgery and adjuvant therapy, avoiding unnecessary overtreatment in a heterogeneous population where T1N-positive disease often carries favourable survival.
Narrative review. Published studies in T1 colorectal cancer reporting determinants of lymph node metastasis, survival patterns, and management outcomes.. Intervention: Structured pathology reporting incorporating lymphovascular invasion, tumour budding, grade, depth, margin status, and morphology..
Lymphovascular invasion and high-grade tumour budding are the most consistent predictors of lymph node metastasis Poor differentiation and submucosal invasion depth add to nodal risk stratification Non-granular pseudo-depressed lateral spreading tumours and depressed lesions signal covert submucosal invasion and indirectly increase nodal risk
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should consider a structured pathology report incorporating lymphovascular invasion, tumour budding grade, differentiation, submucosal invasion depth, margin status, and morphology when deciding whether to offer completion surgery and adjuvant therapy to patients with T1 colorectal cancer, to enable risk-adapted management and reduce overtreatment.
A narrative review synthesizing evidence on risk factors for lymph node metastasis in T1 colorectal cancer and proposing a structured pathology framework to guide clinical decision-making, without new primary data.
As stated by the source record.
Clinicians should consider a structured pathology report incorporating lymphovascular invasion, tumour budding grade, differentiation, submucosal invasion depth, margin status, and morphology when deciding whether to offer completion surgery and adjuvant therapy to patients with T1 colorectal cancer, to enable risk-adapted management and reduce overtreatment.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract T1 colorectal cancer presents a management challenge because a minority of lesions harbour lymph node metastasis (LNM), while T1N-positive disease may demonstrate favourable survival compared with some locally advanced node-negative tumours. This narrative review examines determinants of nodal metastasis in T1 colorectal cancer and considers how these features may inform risk-adapted management. This narrative review was conducted across two databases (MEDLINE and Embase), prioritising studies that used standardised definitions, including International Tumour Budding Consensus Conference (ITBCC) criteria for tumour budding and D2-40 or elastin staining for lymphovascular invasion. The most consistent predictors of lymph node metastasis are lymphovascular invasion and high-grade tumour budding, with poor differentiation and submucosal invasion depth adding to risk. Non-granular pseudo-depressed lateral spreading tumours and depressed lesions appear to signal covert submucosal invasion, indirectly increasing nodal risk. Evidence for tumour site, sex, molecular subtype, and lymphatic vessel distribution remains inconsistent or exploratory. Survival for T1N-positive disease is generally favourable compared with high-risk stage II disease, although comparisons are confounded by nodal burden, stage migration, treatment era, and adjuvant chemotherapy. A structured pathology report incorporating lymphovascular invasion, tumour budding, grade, depth, margin status, and morphology may support balanced decisions regarding completion surgery and adjuvant therapy while avoiding overtreatment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.